U.S.-based cell therapy manufacturing pioneer expands production capacity for European patients with new facility in Leiden. Cellares, the first Integrated Development and Manufacturing Organization (IDMO) for cell therapies headquartered in… Read More
New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO™ beyond lung cancer RARITAN, N.J. – Johnson & Johnson announced… Read More
KIRKLAND, Quebec – Merck, known as MSD outside of the United States and Canada, announced that Health Canada has approved KEYTRUDA SC™ (pembrolizumab injection), a new subcutaneous formulation of pembrolizumab,… Read More
Monthly dosing reduces treatment visits while maintaining established safety and efficacy1,2 Builds on RYBREVANT FASPRO™ FDA approval to deliver the simplest and fastest combination regimen for EGFR+ non-small cell lung cancer1,3-6… Read More
BCIT Foundation and INITIO Medical Group came together to celebrate BCIT’s Nuclear Medicine students and highlight the critical role industry partners play in shaping the future of healthcare in British… Read More
